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Background: Data to guide the management of advanced pulmo-
nary carcinoid (APC) come from retrospective reports and subgroup 
analyses of trials that included mainly extrapulmonary carcinoid 
tumors. We report the largest series to date of 49 patients with locally 
advanced or metastatic pulmonary carcinoid.
Methods: The Johns Hopkins Pathology Database was reviewed for 
APC patients treated between January 1992 and December 2012. 
Data on time to recurrence, progression-free survival, and overall 
survival were estimated by using the Kaplan–Meier method.
Results: Forty-nine patients were treated for APC in the specified 
time period. Median time to recurrence after surgical resection was 
2.5 years (atypical carcinoid [AC] versus typical carcinoid [TC], 2.5 
versus 6.3 years; p = 0.063). Median survival with advanced disease 
was 7.1 years and significantly longer for TC compared with AC (10.2 
versus 4 years; p = 0.009). Among the diverse systemic therapies used, 
responses occurred in four of 17 patients (23.5%) who received plati-
num/etoposide with a median progression-free survival of 7 months.
Conclusion: Although systemic chemotherapy has moderate activity 
for APC, novel approaches are required. TC and AC, although both 
classified as pulmonary carcinoid, are clearly different clinical and 
molecular entities and require separate treatment paradigms in the 
advanced/metastatic setting.
Key Words: Pulmonary carcinoid, Metastatic carcinoid, Chemotherapy 
pulmonary carcinoid, Chemotherapy bronchial carcinoid, Therapy car-
cinoid, Atypical carcinoid, Typical carcinoid.
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The incidence of pulmonary carcinoid (PC) tumors has increased during the last 30 years in part because of a 
combination of asymptomatic tumors being incidentally noted 
on chest imaging and the use of more rigorous histological 
diagnostic criteria.1–3 PC tumors represent 1% to 2% of all 
lung malignancies and approximately 25% of all carcinoid 
tumors originate in the lung.3,4
PC tumors are divided into typical carcinoid (TC) and 
atypical carcinoid (AC) and are classified as foregut neuroen-
docrine tumors (Table 1).1,2 Although the majority of TCs are 
cured by surgical resection, AC represents a more aggressive 
phenotype with frequent recurrences being reported.
METHODS
This retrospective cohort study included all patients 
referred to Johns Hopkins for the management of advanced 
(unresectable, locally advanced, or metastatic) PC between 
January 1, 1992 and December 31, 2012. All patients’ tumor 
specimens were reviewed by the Johns Hopkins pathology 
department and confirmed as PC. Data on time to recurrence, 
progression-free survival (PFS), and overall survival were 
estimated by using the Kaplan–Meier method and log-rank 
test comparing TC and AC.
RESULTS
Patient and Disease Characteristics
Patient characteristics are listed by histologic subtype 
in Table 2. Forty-nine patients were included in this series; 
of these, 32 had AC and 17 had TC. The median age at diag-
nosis of advanced PC (APC) was 56 years (range, 28–79), 
and 61% of patients were women. At a minimum, all patients 
were initially staged and followed with regular computed 
tomography scans of chest and abdomen. The majority of 
patients (53%) were never smokers. Median follow-up was 
54 months (range, 10–183+). Most patients had metastatic 
disease (83.7% versus 16.3% with locally advanced disease 
only), and the commonest sites of metastases throughout the 
course of the disease were liver (59.2% of patients), mediasti-
num or contralateral lung (36.7%), bone (36.7%), and central 
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nervous system (12.2%). All central nervous system metasta-
ses occurred in patients with AC. Only eight patients (16.3%; 
6 TC and 2 AC), all with liver metastases, had symptoms con-
sistent with the carcinoid syndrome. Median survival from 
diagnosis of locally advanced unresectable or metastatic PC 
was 7.1 years and was significantly longer for TC-histology 
patients compared with AC-histology patients (10.2 versus 4 
years; p = 0.009) (Fig. 1B).
Therapy Administered
More than half of the patients (25 of 49 patients) had 
previously undergone lung resections for primary PC. Median 
time to recurrence for patients who underwent curative resec-
tion was 2.5 years, and a trend toward prolonged time to recur-
rence was noted for TC compared with AC (6.3 versus 2.5 
years; p = 0.063) (Fig. 1A).
Six patients (3 AC and 3 TC patients) with locally 
advanced PC received definitive radiation ± concurrent che-
motherapy as primary therapy. This group included three 
patients who received definitive radiation alone (2 TC and 1 
AC patients; radiation dose range, 45 to 67 Gy) and three who 
received concurrent chemotherapy with cisplatin/etoposide or 
carboplatin/paclitaxel (2 AC and 1 TC patients). Overall, from 
this group, five patients had stable disease as best response 
and one patient had progressive disease. Median PFS after 
definitive radiation or chemoradiation was 10 months (range, 
2–117). All six patients who received radiation ± chemo-
therapy for locally advanced disease eventually experienced 
progressive disease; however, four patients (2 AC and 2 TC 
patients) had prolonged stable disease lasting between 2 and 
almost 10 years.
In total, 39 of 49 patients received systemic anti-cancer 
therapy. Etoposide with either cisplatin or carboplatin was 
administered to 17 patients (any line of therapy), of whom, 
four patients (2 AC and 2 TC patients) (23.5%) had a radiologic 
response. Median PFS for all patients who received platinum/
etoposide was 7 months. Long-acting somatostatin analogue 
therapy was administered to 17 patients with only one tumor 
response being noted; however, prolonged stable disease was 
seen in 13 patients (range, 6–25 months). In two patients who 
received everolimus with sandostatin LAR, one pretreated 
patient has had an ongoing partial response for more than 8 
months. Other therapies used comprised a variety of chemo-
therapies and targeted therapies administered mainly on phase 
I clinical trials; however, no tumor responses were seen.
Almost 60% of patients (n = 29) developed liver 
metastases during the course of their disease and of these, 
nine patients (6 AC and 3 TC patients) underwent hepatic 
transarterial chemoembolization (TACE) with cisplatin/
doxorubicin/mitomycin (7 patients) or doxorubicin-eluting 
beads (2 patients). TACE had promising efficacy in this 
cohort with only one patient having progressive disease 
and eight patients (3 partial responses) experiencing pro-
longed stable disease in the liver lasting between 5 and 19+ 
months. In addition, one patient who received therasphere 
 radio-embolization experienced a prolonged partial response 
lasting 24 months. TACE was overall well tolerated; however, 
one patient died from Gram-negative bacteremia related to a 
third TACE procedure.
LITERATURE REVIEW
The only well-described curative option for PC is surgi-
cal resection, and large series have described 10-year overall 
survival rates for resected TC of 82% to 93% and for resected 
AC of 56% to 64%.5,6
The Role of Adjuvant Therapy
There are currently no clear data available on the use of 
adjuvant systemic therapy in PC tumors. On the basis of the 
relatively high rate of recurrence of resected AC and reported 
responses to platinum/etoposide in advanced disease such 
as those reported in our series, the National Comprehensive 
Cancer Network recommends adjuvant cisplatin/etoposide 
for fully resected stage II AC and consideration of adjuvant 
chemoradiation for completely resected stage III disease (cat-
egory 2B evidence).7,8 Observation is recommended at the 
present time for resected stage I AC and stage I to III TC.
Locally Advanced Unresectable PC
There are very limited data to support the use of defini-
tive chemoradiation for PC; however, in the absence of surgi-
cal options, it is recommended for stage IIIB AC.8 For locally 
advanced unresectable TC, definitive radiation without con-
current chemotherapy should be considered.8
Systemic Therapy for Advanced Disease
Evidence to support systemic therapy for APC comes 
from small retrospective series and subgroup analyses of 
clinical trials that enrolled predominantly gastrointestinal 
TABLE 1.  WHO/IASLC Classification of Pulmonary Neuroendocrine Tumors
Grade Nomenclature Histopathologic Characteristics
Low Typical carcinoid Carcinoid morphology, less than two mitoses/10 HPFs, no necrosis, >0.5 cm diameter
Intermediate Atypical carcinoid Carcinoid morphology, two to 10 mitoses/10 HPFs or foci of necrosis
High Large-cell neuroendocrine carcinoma Neuroendocrine structure, >10 mitoses/10 HPFs, necrosis (may be extensive), cytology resembling 
NSCLC, IHC positive for NE markers
Small-cell carcinoma Small cell size, scant cytoplasm, nuclei with finely granular chromatin and faint nucleoli, >11 
mitoses/10 HPFs, extensive necrosis
WHO, World Health Organization; IASLC, International Association for the Study of Lung Cancer; NSCLC, non–small-cell lung cancer; IHC, immunohistochemistry; NE, 
neuroendocrine; HPF, high powered fields.
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TABLE 2.   Patient and Disease Characteristics by Histologic Subtype (N = 49)
Characteristics
Typical (n = 17) Atypical (n = 32)
paNo. % No. %
Age at diagnosis (yr) 0.117
  Median and (IQR) 50 (47–57) 58 (47–64)
Sex 0.715
  Male 6 35.3 13 40.6
  Female 11 64.7 19 59.4
Smoking status 0.234
  Ever smoked 6 35.3 17 53.1
  Never smoked 11 64.7 15 46.9
Prior curative resection 0.845
  Yes 9 52.9 16 50
  No 8 47.1 16 50
Time to recurrence (mo) 0.008b
  Median 119 66
Advanced disease stage (IASLC Seventh Edition) 0.855
  Locally advanced 3 17.7 5 15.6
   IIIA 1 2
   IIIB 2 3
Metastatic (stage IV)  
Stage at initial presentation (TNM)
14 82.3 27 84.4
  T1A/B N0/X M0 2 1
  T1A N2 M0 0 1
  T2A/B N0 M0 1 2
  T2A/B N1 M0 2 0
  T2A/B N2 M0 1 7
  T3 N0 M0 1 0
  T3 N2 M0 0 2
  T3 N3 M0 0 1
  T4 N1 M0 1 0
  T4 N2/3 M0 2 2
  T2B N0 M1A 2 0
  T4 N1 M1A 1 2
  T2A/B N0/X M1B 2 4
  T3 N1/X M1B 1 6
  T4 NX M1B 2 4
Metastatic disease sites
  Liver 10 58.8 19 59.4
  Pleura/mediastinum/contralateral lung 8 47.1 10 31.3
  Bone 7 41.2 11 34.4
  Brain/meninges 0 0 6 18.9
  Other 2 11.8 5 15.6
Carcinoid syndrome 0.015
  Yes 6 35.3 2 6.3
  No 11 64.7 30 93.7
Chromogranin A level (serum) 0.025
  Increased 9 52.9 6 18.8
  Normal 6 35.3 12 37.5
  Result not available 2 11.8 14 43.7
aχ2 test for homogeneity or Fisher’s exact test for binary and categorical variables and nonparametric Mann–Whitney U test for continuous variables.
bLog-rank test.
IQR, interquartile range; IASLC, International Association for the Study of Lung Cancer; TNM, tumor, node, metastasis.
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neuroendocrine tumor patients (Table 3).9–14 Because of the 
rarity of APC, the majority of these studies have reported 
response rates across several different lines of therapy and 
with diverse regimens.
DISCUSSION
Despite surgical resection being the recognized first-line 
treatment of choice, recurrence is not unusual in PC tumors. 
Because of their rarity, thoracic oncologists lack prospective 
data on the optimal management of recurrent or unresect-
able disease. To date, this study is the most comprehensive 
series describing the presentation, disease course, and treat-
ment outcomes of 49 APC patients. In our series, patients 
with TC had a prolonged disease course with a median time to 
recurrence for surgically resected cases of more than 6 years 
compared with 2.5 years for AC although this difference was 
not statistically significant (p = 0.063) given relatively small 
patient numbers. Median survival from time of diagnosis 
of advanced disease was 7.1 years and ranged from 4 years 
for AC patients to more than 10 years for patients with TC 
(p = 0.03). Responses to systemic therapy reported in our 
study demonstrate that platinum/etoposide chemotherapy is a 
moderately effective regimen for both advanced TC and AC 
with 23.5% of patients demonstrating a radiological response. 
This is consistent with the few other published reports in PC 
and confirms the perception of APC as a much less chemo-
responsive disease than small-cell lung cancer. Somatostatin 
analogue therapy is a recognized therapy in carcinoid tumors 
and, although in our experience, it has limited activity in terms 
of tumor radiologic response, several patients did maintain 
prolonged stable disease with this treatment.
Our study has several limitations primarily related to 
being retrospective in nature. Because of small patient num-
bers, it is not possible to reliably describe prognostic factors 
for our cohort other than histology and indeed for rare can-
cers such as APC, the establishment of a prospectively main-
tained multi-institutional database would be very useful in this 
regard. Although 52% of patients analyzed in this cohort had 
previously undergone surgical resection, thus providing ample 
TABLE 3.   Studies of Chemotherapy and Targeted Agents in Locally Advanced or Metastatic Pulmonary Carcinoid
Study and Type
No. of Patients and 
Histology, N Regimen(s)













Granberg et al., Retrospective 
series, 2001
31
27 TC, 4 AC









Wirth et al., Retrospective, 
2004
18
8 TC, 10 AC
Platinum/etoposide-based
(N = 13)
23.1 Not reported 20
Ekeblad et al., Retrospective 
subgroup, 2007
13




Fazio et al., Subgroup analysis 
of prospective study, 2012
44
33 TC, 9 AC, 2 
unknown




0 (67% had minor 
response)
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tumor for analysis, the remainder of diagnoses were made 
using tumor biopsies of varying quantity and quality. Given the 
challenges involved in differentiating AC from TC (Table 1), 
it is conceivable that some patients may have been incor-
rectly categorized. Response rate and PFS for each therapy 
were estimated using both radiology and clinical notes and 
thus reflect real-life practice; however, as a consequence have 
a degree of associated uncertainty.
To our knowledge, this study confirms for the first time, 
the longstanding perception that advanced AC patients have a 
significantly poorer prognosis when compared with patients 
with advanced TC. Given the long natural history of this 
disease uncertainty exists regarding optimal therapy and the 
potential survival benefit associated with systemic therapy, 
both TC and AC tumors demonstrate response to platinum/
etoposide chemotherapy and we consider this to be a standard 
first-line option at our institution. A better understanding of 
the biology of these tumors through advanced technologies, 
such as next-generation sequencing, may help identify poten-
tial markers for prognosis and treatment of advanced cases. 
The rarity of APC prevents us from performing large random-
ized clinical trials specifically for this subgroup of patients. 
Rare diseases may, however, lend themselves perfectly to 
investigation using molecular profiling–directed therapies.
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